On the other hand, the levels of the mesenchymal markers N-cadherin, Twist1 and vimentin were 2.3, 12 and 3 fold higher in breast cancer cells treated with SFCM from TCF-169-CHEK2-siRNA as compared to SFCM from control cells (Fig. 5c). The gene discussed is CHEK2; the disease is breast cancer.